Cargando…

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial

BACKGROUND: The STREAM trial demonstrated that a 9–11-month “short” regimen had non-inferior efficacy and comparable safety to a 20+ month “long” regimen for the treatment of rifampicin-resistant tuberculosis. Imbalance in the components of the composite primary outcome merited further investigation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, P. P. J., Van Deun, A., Ahmed, S., Goodall, R. L., Meredith, S. K., Conradie, F., Chiang, C-Y, Rusen, I. D., Nunn, A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640464/ https://www.ncbi.nlm.nih.gov/pubmed/33143704 http://dx.doi.org/10.1186/s12916-020-01770-z

Ejemplares similares

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
por: Goodall, Ruth L., et al.
Publicado: (2022)

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
por: Nunn, Andrew J, et al.
Publicado: (2014)

QT prolongation in the STREAM Stage 1 Trial
por: Hughes, G., et al.
Publicado: (2022)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial
por: Madan, Jason J, et al.
Publicado: (2020)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens
por: Phillips, Patrick P. J., et al.
Publicado: (2017)

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
por: Van Deun, Armand, et al.
Publicado: (2022)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis
por: Kendall, Emily A., et al.
Publicado: (2021)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study
por: Surey, J., et al.
Publicado: (2021)

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

Preparing the healthcare workforce in South Africa for short-course rifampicin-resistant TB treatment: inter-professional training and task-sharing considerations
por: Farley, Jason E., et al.
Publicado: (2021)

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status
por: Tweed, Conor D., et al.
Publicado: (2019)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Trends in rifampicin resistance among patients with presumptive TB in the pre-COVID and COVID-era
por: Alao, Michael Abel, et al.
Publicado: (2022)

Trends in Rifampicin Resistance Among Children With Presumptive TB in the Pre-COVID and COVID-Era
por: Alao, Michael Abel, et al.
Publicado: (2023)

Prognostic factors among TB and TB/DM comorbidity among patients on short course regimen within Nairobi and Kiambu counties in Kenya
por: Mburu, Josephine W., et al.
Publicado: (2018)

Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries
por: Schwœbel, Valérie, et al.
Publicado: (2020)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e7jkikn6rlfclmqr4lbhtmald4